Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB Therapeutics_resized
IRLAB (OMX: IRLAB-A) publishes preclinical mesdopetam data in journal
Published by Arron Aatkar, PhD

IRLAB Therapeutics has announced the publication of preclinical data on mesdopetam in the prestigious peer-reviewed journal, European Journal of Neuroscience. The research provided insights into the mechanisms behind the antidyskinetic properties of mesdopetam, as well as its potential to address psychosis in Parkinson’s disease patients.

Mesdopetam is IRLAB’s lead clinical asset. Provided the company secures a suitable partner, a Phase III programme in levodopa-induced dyskinesias could be launched within 2025.

Latest

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m

Healthcare | Comment

Mendus (OMX: IMMU) announces c SEK50m directed share issue